Haoxi Health Technology Ltd
About: Haoxi Health Technology Ltd is an online marketing solution provider in China, with an advertiser client base mainly in the healthcare industry. Haoxi has been rooted in the field of local online effect marketing for many years, serving customers in various industries at home and abroad, and its main business is the medical industry. It generates its revenue by providing one-stop online marketing solutions, in particular online short video marketing solutions, to advertisers through its media partners. The company provides customized marketing solutions by planning, producing, placing, and optimizing online ads, especially online short video ads, to help its advertisers acquire, convert, and retain ultimate consumers on various online media platforms.
Employees: 30
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
97% more capital invested
Capital invested by funds: $248K [Q2] → $489K (+$241K) [Q3]
67% more funds holding
Funds holding: 6 [Q2] → 10 (+4) [Q3]
6.98% more ownership
Funds ownership: 0.32% [Q2] → 7.3% (+6.98%) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for HAO.
Financial journalist opinion
Neutral
GlobeNewsWire
3 weeks ago
Haoxi Health Technology Limited Awarded a RMB30 Milllion Framework Contract to Provide Digital Advertising Services for Tengyuan Media Advertising Co., Ltd.
BEIJING, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (the “Company” or “HAO”), an online marketing solution provider headquartered in Beijing, China, today announced the Company's wholly owned subsidiary Beijing Haoxi Digital Technology Co., Ltd. (“Beijing Haoxi”) was awarded a Recharge Service Framework Contract (the “Contract”) to provide comprehensive digital advertising services with a budget of RMB30 million for Tengyuan Media Advertising Co., Ltd. (“Tengyuan") and its clients.
Neutral
GlobeNewsWire
1 month ago
Haoxi Health Technology Limited Reports Financial Results for Fiscal Year Ended June 30, 2024
BEIJING, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (the “Company” or “HAO”), an online marketing solution provider headquartered in Beijing, China, today reported its financial results for the fiscal year ended June 30, 2024.
Neutral
GlobeNewsWire
2 months ago
Haoxi Health Technology Limited Announces Preliminary Unaudited FY24 Financial Results with projected 72% Revenue Growth
BEIJING, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (the “Company” or “HAO”), an online marketing solution provider headquartered in Beijing, China, today announced preliminary unaudited financial results for the fiscal year ended June 30, 2024 (“FY24”).
Neutral
GlobeNewsWire
2 months ago
Haoxi Health Technology Limited and Global Mofy AI Ltd Announce Strategic Partnership to Innovate AI Marketing Solutions
BEIJING, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (the “Company” or “HAO”), an online marketing solution provider headquartered in Beijing, China, today announced a strategic partnership with an AI platform, Gauss Intelligence (Beijing) Technology Co., Ltd., a subsidiary of Global Mofy AI Ltd (Nasdaq: GMM). This collaboration aims to leverage the advanced capabilities of Gausspeed, a cutting-edge generative AI platform, alongside HAO's extensive application scenarios to deliver transformative AI marketing solutions.
Neutral
GlobeNewsWire
3 months ago
Haoxi Health Technology Limited Announces the Closing of a $12 Million Underwritten Follow-on Public Offering
BEIJING, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (the “Company” or “HAO”), an online marketing solution provider headquartered in Beijing, China, today announced that it closed its previously announced underwritten follow-on offering of 4,000,000 units (each a “Unit,” and collectively, the “Units”) at a public offering price of $3.00 per Unit (the “Offering”). Each Unit consists of (i) one share of Class A Ordinary Share, par value $0.0001 per share (the “Class A Ordinary Share”) (or one pre-funded warrant to purchase one Class A Ordinary Share (the “Pre-Funded Warrant”)), (ii) one Series A warrant to purchase one Class A Ordinary Share (the “Series A Warrant”) initially, but five Class A Ordinary Shares on and after the Series B Exercise Date, and (iii) one Series B warrant to purchase four of Class A Ordinary Shares on and after the sixteenth (16th) calendar day (the “Series B Exercise Date”) following the closing of the Offering (the "Series B Warrant”, together with the Series A Warrant, the “Warrants”). The Units have no stand-alone rights and therefore are not certificated or issued as stand-alone securities. The Class A Ordinary Shares and related Warrants are issued separately in the Offering. The Company received aggregate gross proceeds of $12,000,000 from the Offering, before deducting underwriting discounts and other offering expenses, excluding the exercise of any Warrants.
Neutral
GlobeNewsWire
3 months ago
Haoxi Health Technology Limited Announces Pricing of a $12 Million Underwritten Follow-on Public Offering
BEIJING, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (the “Company” or “HAO”), an online marketing solution provider headquartered in Beijing, China, today announced the pricing of its underwritten follow-on public offering (the "Offering") of 4,000,000 units (each a “Unit,” and collectively, the “Units”) at an offering price of $3.00 per Unit (the “Public Offering Price”) for total gross proceeds of $12,000,000, before deducting underwriting discounts and other offering expenses. Each Unit consists of (i) one share of Class A Ordinary Share, par value $0.0001 per share (the “Class A Ordinary Share”) (or one pre-funded warrant to purchase one Class A Ordinary Share (the “Pre-Funded Warrant”)), (ii) one Series A warrant to purchase one Class A Ordinary Share (the “Series A Warrant”) (subject to certain adjustments therein), and (iii) one Series B warrant to purchase such number of Class A Ordinary Share described in the prospectus of the Offering (the "Series B Warrant”, together with the Series A Warrant, the “Warrants”). The Warrants will have a term of 5 years from the closing date of the Offering (the “Closing Date”). The Series A Warrant is exercisable immediately upon issuance, or the Closing Date. The Series B Warrant is exercisable at any time on or after the sixteenth (16th) calendar day from the Closing Date (the “Series B Exercise Date”). The Series A Warrants have an initial exercise price of $3.00 per Class A Ordinary Share. On the Series B Exercise Date, the exercise price of the Series A Warrant will be adjusted to $0.60 and the maximum number of Class A Ordinary Shares issuable upon exercise of the Series A Warrants will be adjusted to 20,000,000 shares. The exercise price of the Series B Warrants is $0.0001 per Class A Ordinary Share. The maximum number of shares issuable upon exercise of the Series B Warrants will be 16,000,000 shares. The Units have no stand-alone rights and will not be certificated or issued as stand-alone securities. The Class A Ordinary Shares, the Pre-Funded Warrants, and related Warrants are immediately separable and will be issued separately in the Offering.
Neutral
Business Wire
6 months ago
Haoxi Health Technology Limited Facilitates International Humanitarian Aid Efforts Amid Global Challenges
BEIJING--(BUSINESS WIRE)--HAO has established a dedicated service team, collaborating closely with medical aid organizations to assess frontline medical supply requirements.
Neutral
GlobeNewsWire
6 months ago
Haoxi Health Technology Limited Reports Unaudited Financial Results for The Six Months Ended December 31, 2023
BEIJING, May 31, 2024 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (the “Company” or “HAO”), an online marketing solution provider headquartered in Beijing, China, today reported its unaudited financial results for the six months ended December 31, 2023.
Neutral
GlobeNewsWire
7 months ago
Haoxi Health Technology Limited Enters into Rebate Agreement with Clients on Advertising Placement Campaign
BEIJING, May 07, 2024 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (the “Company” or “HAO”), an online marketing solution provider headquartered in Beijing, China, today announced that Beijing Haoxi Digital Technology Co., Ltd. (“Haoxi Beijing”), a wholly-owned subsidiary of the Company, entered into a bidding data promotion rebate agreement (the “Rebate Agreement”) on April 29, 2024 with Jinan Yanling Biotechnology Co., Ltd. (“Yanling”) and its subsidiaries and affiliated companies (together, the “Clients”).
Neutral
GlobeNewsWire
7 months ago
Haoxi Health Technology Limited Enters into Advertising Placement Service Framework Contract
BEIJING, May 03, 2024 (GLOBE NEWSWIRE) -- Haoxi Health Technology Limited (the “Company” or “HAO”), an online marketing solution provider headquartered in Beijing, China, today announced that Beijing Haoxi Digital Technology Co., Ltd. (“Haoxi Beijing”), a wholly-owned subsidiary of the Company, entered into a Framework Contract for Cooperation on Information Placement on Media Platforms (the “Framework Contract”) on April 28, 2024 with Wuhan Yiya Simei Dental Clinic Co., Ltd. (“Yiya Dental”), a regional dentistry chain in China. This partnership underscores the Company's capabilities in delivering internet marketing solutions.
Charts implemented using Lightweight Charts™